If the cells you would like to access are currently listed as unavailable
or you are ordering from outside of Europe please get in touch via
Contact@EBiSC.org.
UKKi007-B
NP0014-5
iPSC line
Timepoint: 48 hours post-passage
Magnification: 4x
Magnification: 4x
Timepoint: 48 hours post-passage
Magnification: 10x
Magnification: 10x
Timepoint: Confluence
Magnification: 4x
Magnification: 4x
Timepoint: Confluence
Magnification: 10x
Magnification: 10x
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg name | UKKi007-B |
| Alternative name(s) |
NP0014-5
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi007-A (NP0014-6, UKK007Ai) Donor's gene variants: RYR2, RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia |
Provider |
|
| Depositor | Klinikum der Universität zu Köln (UKK) |
| Owner | Institute for Neurophysiology, Medical Faculty |
| Distributors |
EBiSC
Institute for Neurophysiology, Medical Faculty
Scottish Centre for Regenerative Medicine
|
External Databases |
|
| hPSCreg | UKKi007-B |
| BioSamples | SAMEA2698638 |
| Cellosaurus | CVCL_9S36 |
| Wikidata | Q54990423 |
General Information |
|
| Publications |
|
| This EBiSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 45-49 |
| Ethnicity | Caucasian, German |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | de novo mutation |
| Is the medical history available upon request? | No (can be retreived upon request) |
| Is clinical information available? | Not available |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA2629512 |
hIPSC Derivation#
General |
|
| Source cell type |
Any skin fibroblast that is part of some dermis.
|
| Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
| Age of donor (at collection) | 45-49 |
| Collected in | 2009 |
| Passage number reprogrammed | P3 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
RT-PCR
|
| Vector map | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | human ESC morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | Essential E8 |
| Passage method | EDTA |
| Surface coating | Vitronectin |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| TRA1-80 |
Yes |
|
|
Morphology pictures
Brighfield image of NP0014-5 colony at day 3 post-thaw at higher mahnification; 32x objective
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| HAND1 |
Yes |
| VIMENTIN |
Yes |
| BMP4 |
Yes |
| GATA4 |
No |
| DCN |
Yes |
| PECAM1 (CD31) |
Yes |
| PDGF |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| SOX17 |
Yes |
| FOXA2 |
No |
| GSC |
Yes |
| GATA6 |
Yes |
| CXCR4 |
Yes |
| PITX1 |
Yes |
| MYH6, alpha myosin heavy chain |
Yes |
| MLC2v, myosin light chain 2v |
Yes |
| ACTN2, cardiac alpha actinin |
Yes |
| RYR2 |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| PAX6 |
Yes |
| Sox1 |
Yes |
| B-TUBULIN |
Yes |
| NEUROD1 |
Yes |
| HES5 |
Yes |
| FOXG1 |
No |
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX
Passage number: 34
Karyotyping method:
Molecular karyotyping using using OmniExpress Exome Chip
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP-genotyping using OmniExpress Exome Chip
|